Summary
Forty-two previously untreated patients with metastatic malignant melanoma were randomized to receive DTIC at a dose of 250 mg/m2/day 4 IV on days 1–5 or the same drug plus epirubicin (Epi-DX) at a dose of 90 mg/m2 on day 1. Cycles were repeated every 3 weeks. Partial responses were observed in two out of 22 patients (9.1%) treated with DTIC, and in four out of 19 evaluable patients (21.1%) treated with Epi-DX+DTIC. Overall, Epi-DX+DTIC combination was well tolerated, thus permitting administration after a 3-week interval of the full drug dosages in all but two patients. No major cardiotoxicity was observed. Although patients in the Epi-DX+DTIC group had a better response rate than those in the DTIC group, the difference was not statistically significant, and the 21.1% response rate observed with the two-drug combination does not differ from that reported with DTIC used alone.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bellet RE, Mastrangelo MJ, Berd D, Lustbader E: Chemotherapy of metastatic malignant melanoma. In Clark WH, Goldman LI, Mastrangelo HJ (eds): Human Malignant Melanoma. Grune & Stratton, New York, 1979, pp 325–351
Ganzina F.: 4′-Epidoxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10:1–22, 1983
Bonfante V, Villani F, Bonadonna G: Toxic and therapeutic activity of 4′-epi-doxorubicin. Tumori 68:105–111, 1982
Griswold DP, Laster WR Jr, Schabel FM Jr: Therapeutic potentiation by adriamycin and 5-(3,3-dimethyl-triazeno)-imidazole-4-carboxamide against B16 melanoma, C3H breast carcinoma, Lewis lung carcinoma and leukemia L1210. (Abstract) Proc Am Assoc Cancer Res 14:15, 1973
Goldin A: Some factors influencing the chemotherapeutic effectiveness of adriamycin. In Carter SK, Di Marco A, Ghione M, Krakoff IH, Mathé G (eds): International Symposium on Adriamycin. Springer-Verlag, Berlin-Heidelberg, 1972, pp 64–74
Gottlieb JA, Baker LH, Quagliana JM, Luce JK, Whitecar JP, Sinkovics JG, Rivkin SE, Brownlee R, Frei III E: Chemotherapy of sarcomas with a combination of adriamycin and dimethyl-triazeno-imidazole-carboxamide. Cancer 30:1632–1638, 1972
Gottlieb JA, Baker LH, O'Bryan RM, Sinkovics JG, Hoogstraten B, Quagliana JM, Rivkin SO, Bodey G, Rodriguez Sr. V, Blumenschein GR, Saiki JH, Coltman C Jr, Burgess HA, Sullivan P, Tighpen T, Bottomley R, Balcerzak S, Moon TE: Adriamycin (NSC-123127) used alone and in combination for soft tissue and bony sarcomas. Cancer Chemother Rep (Part 3) 6:271–282, 1975
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Lopez M, Perno CF, Papaldo P, Di Lauro L, Ganzina F, Barduagni A: Phase II study of Epirubicin in advanced malignant melanoma. Invest N Drugs 2:315–317, 1984 (this issue)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lopez, M., Perno, CF., Di Lauro, L. et al. Controlled study of DTIC versus DTIC plus epirubicin in metastatic malignant melanoma. Invest New Drugs 2, 319–322 (1984). https://doi.org/10.1007/BF00175384
Issue Date:
DOI: https://doi.org/10.1007/BF00175384